Steve Beuchaw

In a report published Monday, Morgan Stanley analyst Steve Beuchaw initiated coverage on Myriad Genetics, Inc. (NASDAQ: MYGN) with an Underweight rating and $25.00 price target. In the report, Morgan Stanley noted, “We forecast 28% share loss and 42% price declines by '17 in the BRCA franchise,...

In a report published Tuesday, Morgan Stanley analyst Steve Beuchaw reiterated an Equal-Weight rating on Agilent Technologies (NYSE: A), but lowered the price target from $62.00 to $59.00. In the report, Morgan Stanley noted, “Lowering Agilent price target to $59 from $62 to reflect peer multiples...

In a report published Monday, Morgan Stanley analyst Steve Beuchaw reiterated an Underweight rating on Varian Medical Systems, Inc. (NYSE: VAR), but removed the $76.00 price target. In the report, Morgan Stanley noted, “ASTRO's reimbursement update confirmed that a new radiation oncology rate...

In a report published Monday, Morgan Stanley analyst Steve Beuchaw reiterated an Overweight rating and $81.00 price target on Sirona Dental Systems (NASDAQ: SIRO). In the report, Morgan Stanley noted, “Sirona has the most compelling lineup of practice-enabling technology for dentistry. Exclusive...

In a report published Wednesday, Morgan Stanley analyst Steve Beuchaw reiterated an Underweight rating on Varian Medical Systems (NYSE: VAR), but removed the $76.00 price target. In the report, Morgan Stanley noted, “Financial takeaways in line with our expectations; Oncology revenue still the key...

In a report published Wednesday, Morgan Stanley analyst Steve Beuchaw reiterated an Equal-Weight rating on DENTSPLY International (NASDAQ: XRAY). In the report, Morgan Stanley noted, “Dentsply is the largest and best managed diversified supplier of dental and orthodontic products, but subject to...

In a report published Monday, Morgan Stanley analyst Steve Beuchaw reiterated an Overweight rating on Sirona Dental Systems (NASDAQ: SIRO), and raised the price target from $78.00 to $81.00. In the report, Morgan Stanley noted, “Sirona has the most compelling lineup of practice-enabling technology...

In a report published Thursday, Morgan Stanley analyst Steve Beuchaw maintained Underweight on Varian Medical Systems (NYSE: VAR), with a $71.00 price target. According to the report, orders missed consensus by 3 percent in Oncology and 12 percent overall, though US Oncology rebounded after a...